Pacira Other Current Liab from 2010 to 2025

PCRX Stock  USD 24.42  0.12  0.49%   
Pacira BioSciences, Other Current Liabilities yearly trend continues to be fairly stable with very little volatility. Other Current Liabilities is likely to outpace its year average in 2025. During the period from 2010 to 2025, Pacira BioSciences, Other Current Liabilities regression line of annual values had r-squared of  0.61 and arithmetic mean of  73,169,062. View All Fundamentals
 
Other Current Liabilities  
First Reported
2008-12-31
Previous Quarter
76.4 M
Current Value
80.1 M
Quarterly Volatility
28.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 82.7 M, Interest Expense of 15.8 M or Selling General Administrative of 67.3 M, as well as many indicators such as Price To Sales Ratio of 1.18, Dividend Yield of 0.0014 or PTB Ratio of 1.06. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
  
Check out the analysis of Pacira BioSciences, Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Latest Pacira BioSciences,'s Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Pacira BioSciences, over the last few years. It is Pacira BioSciences,'s Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Pacira Other Current Liab Regression Statistics

Arithmetic Mean73,169,062
Geometric Mean31,583,503
Coefficient Of Variation124.09
Mean Deviation63,247,336
Median41,133,000
Standard Deviation90,795,680
Sample Variance8243.9T
Range295.2M
R-Value0.78
Mean Square Error3437.9T
R-Squared0.61
Significance0.0003
Slope14,904,360
Total Sum of Squares123657.8T

Pacira Other Current Liab History

2025296 M
2024281.9 M
202364.2 M
202280.7 M
2021127.6 M
202085.7 M
201918.2 M

About Pacira BioSciences, Financial Statements

Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Other Current Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Current Liabilities281.9 M296 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.